期刊
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY
卷 48, 期 3, 页码 292-294出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnmt.119.237354
关键词
sinonasal neuroendocrine carcinoma; Ga-68-DOTATATE PET/CT; F-18-FDG PET/CT; Lu-177-DOTATATE; peptide receptor radionuclide therapy; dual-tracer PET/CT
Sinonasal neuroendocrine carcinomas (SNCs), in contrast to neuroendocrine carcinomas at other sites, are notorious for their recurrent and locally aggressive nature. The clinical concern is primarily due to their complex anatomy and close proximity to vital structures, compounded by lack of proper understanding of pathogenesis, no definitive classification or staging system, and no established treatment guidelines. We present the promise of combined treatment with Lu-177-DOTATATE-based peptide receptor radionuclide therapy (PRRT) and platinum-based chemotherapy in a patient with high-grade, recurrent, and metastatic SNC (that demonstrated high uptake on both Ga-68-DOTATATE and F-18-FDG PET/CT), which showed a significant partial response. The case report highlights the feasibility and effectiveness of applying a combined protocol of Lu-177-DOTATATE and platinum-based chemotherapy in the management of high-grade, recurrent, metastatic SNC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据